Completed PHASE2 INTERVENTIONAL 2-arm NCT06149494

RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection

A Trial in Participants With Chronic Obstructive Pulmonary Disease (COPD) to Evaluate the Impact of Vapendavir on the Development of Lower Respiratory Tract Symptoms Following Rhinovirus Challenge

Sponsor: Altesa Biosciences, Inc.

Conditions COPD Exacerbation Acute COPD With Acute Lower Respiratory Infection Chronic Lower Respiratory Diseases Chronic Respiratory Disease Copd Emphysema or COPD Enterovirus Enterovirus Infections Infection Viral Infections Infections, Respiratory Lower Respiratory Disease Lower Respiratory Disorder Lower Respiratory Tract and Lung Infections Lung Disease Chronic Lung Diseases Obstructive Pulmonary Disease Pulmonary Disease Pulmonary Disease, Chronic Obstructive Respiratory Complication Respiratory Disease Respiratory Disease Chronic Respiratory Tract Diseases Respiratory Tract Infections Respiratory Viral Infection Rhinovirus Rhinovirus Infection Upper Resp Tract Infection Upper Respiratory Disease Upper Respiratory Disease, Acute Upper Respiratory Disorder Upper Respiratory Infection Viral Upper Respiratory Tract Infections Viral Infection Virus Diseases Virus Infection, RNA

Interventions Placebo Vapendavir

Updated 6 times since 2023 Last updated: Sep 29, 2025 Started: Nov 20, 2023 Primary completion: Mar 30, 2025 Completion: Mar 30, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on COPD Exacerbation Acute and COPD With Acute Lower Respiratory Infection, this trial is completed. The trial is conducted by Altesa Biosciences, Inc. and has accumulated 6 data snapshots since 2023. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Oct 2025 — Present [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Mar 2025 — Oct 2025 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Sep 2024 — Mar 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Mar 2024 — Jul 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Dec 2023 — Mar 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Nov 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Altesa Biosciences, Inc.
Virtus Respiratory Research

Data source: Altesa Biosciences, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom